T. Rowe Price Associates’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.71M | Sell |
306,059
-17,883
| -6% | -$158K | ﹤0.01% | 1513 |
|
|
2025
Q1 | $3.49M | Sell |
323,942
-21,595
| -6% | -$232K | ﹤0.01% | 1370 |
|
|
2024
Q4 | $4.42M | Sell |
345,537
-22,077
| -6% | -$283K | ﹤0.01% | 1317 |
|
|
2024
Q3 | $10.1M | Sell |
367,614
-26,004
| -7% | -$718K | ﹤0.01% | 1141 |
|
|
2024
Q2 | $11.4M | Buy |
393,618
+57,044
| +17% | +$1.65M | ﹤0.01% | 1088 |
|
|
2024
Q1 | $15M | Buy |
336,574
+4,630
| +1% | +$207K | ﹤0.01% | 1042 |
|
|
2023
Q4 | $12.9M | Sell |
331,944
-2,366
| -0.7% | -$91.8K | ﹤0.01% | 1045 |
|
|
2023
Q3 | $9.83M | Sell |
334,310
-73,745
| -18% | -$2.17M | ﹤0.01% | 1072 |
|
|
2023
Q2 | $26M | Buy |
408,055
+209,688
| +106% | +$13.3M | ﹤0.01% | 865 |
|
|
2023
Q1 | $9.36M | Buy |
198,367
+14,583
| +8% | +$688K | ﹤0.01% | 1071 |
|
|
2022
Q4 | $12.8M | Sell |
183,784
-81,546
| -31% | -$5.66M | ﹤0.01% | 1012 |
|
|
2022
Q3 | $38.9M | Sell |
265,330
-1,045
| -0.4% | -$153K | 0.01% | 724 |
|
|
2022
Q2 | $34.7M | Sell |
266,375
-8,321
| -3% | -$1.09M | ﹤0.01% | 993 |
|
|
2022
Q1 | $27.7M | Buy |
274,696
+17,631
| +7% | +$1.78M | ﹤0.01% | 1143 |
|
|
2021
Q4 | $39.8M | Buy |
257,065
+74,101
| +41% | +$11.5M | ﹤0.01% | 1081 |
|
|
2021
Q3 | $54.2M | Buy |
182,964
+57,964
| +46% | +$17.2M | 0.01% | 975 |
|
|
2021
Q2 | $40.6M | Buy |
+125,000
| New | +$40.6M | ﹤0.01% | 1105 |
|